IRIX — IRIDEX Corporation

IRIDEX Corporation Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Full Year Revenue: $52.7 million, an 8% increase year-over-year.
• Fourth Quarter Revenue: $14.7 million, a 16% increase compared to Q4 2024.
• Gross Profit: $5.5 million with a gross margin of 37%, down from 44% in 2024 due to increased manufacturing costs and inventory write-downs.
• Operating Expenses: Reduced by 22% year-over-year to $5.5 million.
• Net Loss: $200,000, or $0.01 per share, improved from a loss of $800,000, or $0.05 per share, in 2024.
• Adjusted EBITDA: Positive at $817,000, an improvement from $611,000 in 2024.
• Cash Position: $6 million at the end of Q4, with a significant reduction in cash burn (71% improvement).

2. Strategic Updates and Business Highlights:

• Successful transformation efforts led to sustainable profitability and positive cash flow generation.
• Growth across all major product categories, particularly in glaucoma and retina segments.
• Continued relocation of general and administrative functions out of California, expected to save approximately $165,000 quarterly starting Q1 2026.
• Transitioning production to lower-cost third-party manufacturers, expected to enhance gross margins by 2027.
• Strong performance at the American Academy of Ophthalmology meeting, generating close to $1 million in business from leads.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Expected to be between $51 million and $53 million, excluding Middle East revenue due to ongoing conflicts, which historically contributed 5% of total revenue.
• Anticipated growth of 1% to 5% compared to 2025 when adjusted for Middle East revenue.
• Expectation of positive cash flow throughout 2026, with the first quarter typically being the lowest revenue quarter.

4. Bad News, Challenges, or Points of Concern:

• Declining gross margins due to increased manufacturing costs and tariff impacts.
• Sales in the Middle East are materially impacted by regional conflicts, posing a risk to revenue forecasts.
• Operational challenges in Asia, particularly related to tariffs and currency pressures, which could affect sales and forecasting.
• Some segments, like the "other revenue" line, showed variability, indicating potential instability in certain service product lines.

5. Notable Q&A Insights:

• The Middle East accounts for 5% of total revenue and 10% of U.S. revenue, indicating a significant impact from regional instability.
• The decline in the "other revenue" segment is attributed to variability in service demand rather than a specific trend.
• Despite some pricing pressures, ASPs for G6 probes have increased, and volume sales are up.
• The company believes it is gaining market share in the retina segment, particularly with the PASCAL system, which is expected to see increased momentum with more regulatory approvals.

Overall, IRIDEX Corporation demonstrated a solid performance in Q4 2025, with strategic initiatives aimed at improving profitability and operational efficiency, although challenges in certain regions and segments remain a concern.